Contact this trialFirst, we need to learn more about you.
Virus Therapy
MEM-288 + Nivolumab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Tampa, Florida
This trial is designed to find the maximum tolerated dose of MEM-288 monotherapy, and to see if the oncolytic effect of MEM-288 can provide a strong signal for dendritic cell-mediated T cell activation, leading to the generation of systemic anti-tumor T cell responses.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.